We examined the effects of intra-BM-BMT (IBM-BMT) plus adult thymus transplantation (ATT) from the same donor after 5.5 Gy sublethal irradiation (SubLI) or lowdose (3 Â 10 6 ) BM cell injection (LDBMCI). With SubLI, BALB/c mice that had received 1 Â 10 7 bone marrow cells by IBM-BMT plus ATT from B6 mice showed 73% donor chimerism, whereas those treated with IBM-BMT alone showed 45% chimerism. In the LDBMCI with 7Gy irradiation, IBM-BMT plus ATT resulted in a 90% survival rate with 90% chimerism, whereas IBM-BMT alone resulted in a 55% survival rate with 44% chimerism. Although the number of CD4 T cells was higher in IBM-BMT plus ATT than in IBM-BMT alone, the percentages of FoxP3 þ /CD4 þ T cells and lymphocyte functions in the former were almost identical to those in the latter. When treated with IBM-BMT plus donor lymphocyte infusion (DLI), the mice showed a reduced survival time as a result of GVHD, with low numbers of FoxP3 þ CD4 T cells under either condition, although 100% chimerism was induced. These results suggest that IBM-BMT plus ATT is effective in reconstituting the recipients with donor-derived cells even after SubLI or LDBMCI.
Introduction
BMT has been used as a potentially curative therapy for patients with a wide variety of diseases, including hematological disorders, congenital immunodeficiencies, metabolic disorders, autoimmune diseases and solid tumors. [1] [2] [3] [4] [5] [6] However, there are some factors to take into account to ensure that BMT is performed safely and effectively. It is, for example, important to reduce the dose of irradiation to prevent side effects such as radiation-induced organ injury. 7, 8 To resolve these problems, attempts have been made to transplant high doses of hemopoietic stem cells (HSCs), and/or carry out donor lymphocyte infusion (DLI). 9, 10 However, there may be difficulties in obtaining sufficient numbers of HSCs, or lethal GVHD may be induced by DLI. The development of a new cell-based method is therefore required.
We have developed various new allogeneic BMT methods in mice. To supply recipients with MHC -matched donor BM stromal cells, we previously performed BMT plus bone grafts from the same donor. 5 To induce extramedullary hematopoiesis in the liver, we injected whole BM cells (BMCs; HSCs and stromal cells) from the portal vein. 11 Finally, we have recently developed intra-BM (IBM)-BMT, in which BMCs are directly injected into the BM cavity. 12 We have also developed concurrent thymus transplantation (TT) with BMT; BMT plus TT was found to be effective for recipients showing thymic involution caused by aging, supralethal irradiation, chimeric resistance or malignant tumor. [13] [14] [15] [16] However, it is unknown whether BMT plus TT is effective when using a nonmyeloablative regimen and/or when transplanting insufficient numbers of BMCs. In addition, TT has only been clinically applied to patients with DiGeorge syndrome or HIV infection who show hypoplasia of the thymus; 17, 18 the effects of TT on BMT have not been extensively examined.
In this study, we, therefore, examined the effects of adult TT (ATT) with IBM-BMT from the same donor under the condition of sublethal irradiation (SubLI) or low-dose BMC injection (LDBMCI) in an attempt to resolve the abovementioned limitations.
Materials and methods

Mice
Six-to eight-week-old female BALB/c mice (H-2 d ) and agematched female C57BL/6(B6) (H-2 b ) mice were obtained from Shimizu Laboratory Supplies (Shizuoka, Japan). All mice were kept in our animal facilities under specific pathogen-free conditions. B6 mice were used as donors and BALB/c mice were used as recipients.
BMT, ATT and DLI For SubLI, the recipient BALB/c mice were 5.5 Gyirradiated using a 137 Cs irradiator (0.9 Gy/min) 1 day before BMT. BMCs were flushed from the shafts of the femora and tibias of donor mice (B6) and single-cell suspensions were prepared. BMCs (1 Â 10 7 ) were injected directly into the BM cavity of the tibia, as described earlier for the IBM-BMT method. 12 To ensure the LDBMCI, the recipient BALB/c mice were lethally irradiated (7.0 Gy) 1 day before BMT; BALB/c mice are radiosensitive and 7.0 Gy is the lethal dose for BALB/c mice. BMCs (3 Â 10 6 ) from the B6 mice were injected directly into the BM cavity by the IBM-BMT method. A quarter of the removed thymic lobe from the donor B6 mice was grafted simultaneously under the renal capsule of the left kidney as ATT, or 1 Â 10 7 of spleen cells from the donor B6 mice were i.v. transplanted as a DLI. The dose of the DLI was determined in our earlier study. 16 
Pathologic findings
The transplanted thymus, liver and small intestine from the chimeric mice were fixed in 10% formaldehyde solution and embedded in paraffin. Serial tissue sections 4 mm thick were prepared and stained with hematoxylin-eosin (HE). The histology was examined under the microscope. The degree of GVHD was evaluated using a semiquantitative scoring system for abnormalities known to be associated with GVHD, as previously described. 16 The scoring system for each parameter denotes 0 as normal; 0.5 as focal and rare, 1 as focal and mild, 2 as diffuse and mild; 3 as diffuse and moderate, and 4 as diffuse and severe in GVHD. The maximum score for the liver was thus 40, and for the small intestine it was 28.
Flow cytometry
Surface markers on lymphocytes from peripheral blood and the spleen were analyzed under three-color fluorescence staining using a FACScan system (Becton Dickinson, Franklin Lakes, NJ, USA). FITC-conjugated anti-H-2K b (Pharmingen, San Diego, CA, USA) was used to determine chimerism. Phycoerythrin or biotin-conjugated CD4 or CD8 (Pharmingen) was used to analyze lymphocyte subsets. Avidin-PE-Cy5 (Dako, Kyoto, Japan) was used as the third color in the avidin/biotin system. Intracytoplasmic FoxP3 staining was performed in spleen cells using an FITC-antimouse/rat FoxP3 staining set (eBioscience, San Diego, CA, USA). The procedure was performed in accordance with the instructions of the manufacturer. Donor-derived chimerism was determined from the presence of more than 90% H-2K b þ cells by flow cytometry in the peripheral blood of the chimeric mice 2-4 weeks after BMT.
Mitogen response and MLR
To analyze lymphocyte function and tolerance, mitogen response and MLR were performed in chimeric mice 2 months after transplantation. For mitogen response, a total of 2 Â 10 5 splenocytes collected from chimeric mice and untreated B6 and BALB/c mice as responders were plated in 96-well flat-bottomed plates (Corning Glass Works, Corning, NY, USA) containing 200 ml of RPMI 1640 medium (Nissui Seiyaku, Tokyo, Japan) supplemented with 2 ml of glutamine (Wako Pure Chemicals, Tokyo, Japan), penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% (Figure 1a ). With LDBMCI, the BALB/c mice that had received IBM-BMT plus ATT showed a significantly higher survival rate than did the mice treated with IBM-BMT alone (Figure 1b ). With either SubLI or LDBMCI, the mice treated with IBM-BMT plus ATT survived more than 6 months (data not shown). In contrast, the mice that had received BMCs by IBM-BMT plus DLI (1 Â 10 7 spleen cells) as a GVHD model showed the shortest survival under either condition, most of them having died within 5 weeks of the transplantation (described later). In the analyses of body weight, although the BALB/c mice treated with IBM-BMT plus ATT showed a slight decrease in body weight compared with the mice that were treated with IBM-BMT alone, there was no significant difference between them under either condition ( Figure 2 ). In contrast, the mice treated with IBM-BMT plus DLI showed a significant weight loss because of GVHD under both conditions.
Effects of chimerism in mice treated with IBM-BMT alone or IBM-BMT plus ATT under condition of SubLI or LDBMCI Next, we investigated donor-type chimerism in mice treated with IBM-BMT alone or IBM-BMT plus ATT under the condition of SubLI or LDBMCI 4 weeks after transplantation. Under SubLI, the mice treated with IBM-BMT alone showed 45.5% donor chimerism, whereas the mice treated with IBM-BMT plus ATT showed 72.7% donor chimerism (Table 1) . Under the condition of LDBMCI, in the case of lethal irradiation (7 Gy), the mice treated with IBM-BMT alone showed 44.4% donor chimerism, whereas the mice that had received IBM-BMT plus ATT showed 80% donor ) of BMCs from B6 mice by IBM-BMT plus ATT or IBM-BMT alone under the condition of LDBMCI (b). *Po0.01 compared with the mice that received IBM-BMT alone or IBM-BMT plus ATT at 4 weeks after transplantation. **Po0.01 compared with the mice that received IBM-BMT alone or Po0.05 compared with IBM-BMT plus ATT at 2-4 weeks after transplantation because of early death. w, all mice died. ATT, adult thymus transplantation; DLI, donor lymphocyte infusion; IBM-BMT, intra-BM-BMT; LDBMCI, low-dose BM cell injection; SubLI, sublethal irradiation.
Effect of ATT with IBM-BMT on SubLI and LDBMCI T Nishida et al chimerism ( Table 1) . As the mice treated with IBM-BMT plus DLI died early, we analyzed the mice 2-4 weeks after transplantation. The mice that had received IBM-BMT plus DLI showed 100% donor chimerism under both conditions.
Histology of transplanted thymus from mice treated with IBM-BMT plus ATT In histological analyses, the engrafted thymus showed a normal structure under the renal capsule, and normal T-cell differentiation was observed in the thymus of the mice treated with IBM-BMT plus ATT, under the condition of SubLI, 8 weeks after transplantation (Figure 3a) . The transplanted thymus from the mice that had received IBM-BMT plus ATT under the condition of LDBMCI also showed the same results (data not shown).
Liver and small intestine histology in mice treated with IBM-BMT alone or IBM-BMT plus ATT or DLI under condition of SubLI or LDBMCI In the liver, the mice treated with IBM-BMT plus ATT showed mild lymphocyte infiltration and the GVHD score in liver was as low as that of the mice treated with IBM-BMT alone. In contrast, severe lymphocyte infiltration was observed with bile duct destruction in the mice treated with IBM-BMT plus DLI under either condition, comparable to a finding of GVHD (Figure 3b ). The GVHD score was significantly higher in the mice treated with IBM-BMT plus DLI than in the mice treated with IBM-BMT alone; all these mice died of GVHD within 5 weeks after BMT. In addition, although a number of lymphocytes also infiltrated the mucosa of the small intestine with some fibrosis in the mice treated with IBM-BMT plus DLI, such findings were minimal or nonexistent in the mice treated with either IBM-BMT plus ATT or IBM-BMT alone. The GVHD score in the small intestine of the mice treated with IBM-BMT plus ATT was also as low as that of the mice treated with IBM-BMT alone.
Effects of lymphocyte subsets for mice treated with IBM-BMT alone or IBM-BMT plus ATT or DLI under condition of SubLI or LDBMCI We further analyzed lymphocyte subsets in mice treated with IBM-BMT alone or IBM-BMT plus ATT under the condition of SubLI or LDBMCI 4 weeks after transplantation. As the mice treated with IBM-BMT plus DLI died early, we analyzed the mice 2-4 weeks after transplantation. In the spleen, the number of CD4T cells was highest in the mice treated with IBM-BMT plus ATT, second in the mice treated with IBM-BMT alone, and lowest in the mice treated with IBM-BMT plus DLI (Figure 4) . In contrast, the number of CD8T cells in IBM-BMT plus ATT was almost the same as that in IBM-BMT alone, and significantly higher than that in IBM-BMT plus DLI. The number of B220 þ B cells was highest in the mice treated with IBM-BMT alone, second in the mice treated with IBM-BMT plus ATT and lowest in the mice treated with IBM-BMT plus DLI. We also examined the CD4 þ
FoxP3
þ regulatory T (T reg ) cells ( Figure 5 ), which suppress immune responses. 19 Interestingly, although the number of T reg cells in the mice treated with IBM-BMT plus ATT was significantly higher than that in the mice treated with IBM-BMT alone, the percentages of T reg cells in the CD4T cells from the former were comparable to the latter under either condition (Figure 5b ). However, although the percentages of CD4T cells were also high in the spleens from mice treated with IBM-BMT plus DLI (Figure 5a ), the numbers and the percentages in CD4T cells of the FoxP3 þ T reg cells were the lowest under either condition (Figure 5b ).
Lymphocyte function in the spleen of mice treated with IBM-BMT alone or IBM-BMT plus ATT or DLI under condition of SubLI or LDBMCI Finally, we examined the lymphocyte functions in the spleen from mice treated with IBM-BMT alone or IBM-BMT plus ATT under the condition of SubLI or LDBMCI. Spleen cells in both groups showed sufficient mitogen responses to both Con A and lipopolysaccharide , the levels being comparable with those of normal B6 and BALB/c mice (Figure 6a) . However, the responses were remarkably reduced in the mice treated with IBM-BMT plus DLI under the condition of SubLI or LDBMCI. The assay for MLR revealed that T cells from the mice treated with IBM-BMT alone or IBM-BMTplus ATT under the condition of SubLI or LDBMCI showed tolerance to both BALB/c (host type) and B6 (donor type) MHC determinants but normal responsiveness to third-party (C3H type) MHC determinants ( Figure 6b ). As expected, T cells from the mice treated with IBM-BMT plus DLI under either set of conditions showed responsiveness not only to a third-party (C3H-type) but also to BALB/c (host-type) MHC determinants; it should be noted that T cells from mice treated with IBM-BMT plus DLI showed marked responsiveness to BALB/c (host-type) MHC determinants resulting from GVHD. 
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Discussion
In this study, we have examined the effects of ATT on allogeneic IBM-BMT under the condition of SubLI or LDBMCI. Mice treated with IBM-BMT plus ATT showed a significantly long survival rate and high donor chimerism in comparison with the mice treated with IBM-BMT alone or IBM-BMT plus ATT under either condition. Although the numbers of CD4T cells in the mice treated with IBM-BMT plus ATT were significantly higher than in the mice treated with IBM-BMT alone, the percentages of T reg cells in CD4T cells from the mice treated with IBM-BMT plus ATT were similar to those in the mice treated with IBM-BMT alone; the percentages were significantly higher than those in the mice treated with IBM-BMT plus DLI, which show lethal GVHD. Finally, the mice treated with IBM-BMT plus ATT showed sufficient lymphocyte functions but tolerance to both donor-type and recipient-type MHC determinants. These findings indicate that under the condition of SubLI or LDBMCI, IBM-BMT plus ATT is superior to IBM-BMT alone. First, we examined the effects of ATT on the survival rate and chimerism under the condition of SubLI or LDBMCI. Under the condition of SubLI, the mice treated with IBM-BMT alone and the mice treated with IBM-BMT plus ATT survived for a long time (Figure 1) . However, the chimerism in the latter was much greater than in the former (Table 1) . Under the condition of LDBMCI, the mice treated with IBM-BMT plus ATT showed a significantly longer survival rate with a higher percentage of donor The cause of death in the mice treated with IBM-BMT alone was graft failure because of the low percentage of chimerism. In contrast, under either condition, the mice treated with IBM-BMT plus DLI showed a significantly short survival with GVHD (Figures 2 and 3) , even when they showed 100% donor chimerism. Although the mice treated with either IBM-BMT plus ATT or IBM-BMT alone showed little weight gain, they survived a long time and showed no apparent histological findings of GVHD, suggesting the nondevelopment of severe or lethal GVHD, as we reported earlier in MRL/lpr 12 and normal mice 20 or tumor-bearing mice. 21 These results indicate that IBM-BMT plus ATT is superior to the other strategies for survival and/or chimerism.
Second, we studied the donor-derived lymphocyte subsets under the condition of SubLI or LDBMCI. The numbers of CD4T cells in the mice treated with IBM-BMT plus ATT were significantly higher than in the mice treated with IBM-BMT alone (Figure 4) . In contrast, the numbers of CD8T cells were no different between the mice treated with IBM-BMT plus ATT or not. Although the reason for this discrepancy is unclear, we also observed the same in newborn TT with BMT in supralethally irradiated mice. 15 Transplanted thymus may predominantly supply CD4T cells or suppress CD8T cells. The low number of all lymphocyte subsets in the mice treated with IBM-BMT plus DLI may be the result of the GVHD. 22 From the above results, there is a clear correlation between the involvement of mature T cells in transplanted cells and donor chimerism, suggesting that the alloresponse of the T cells plays an important role in reconstituting the recipients with donor cells. However, severe GVHD was not evident in the mice treated with IBM-BMT plus ATT. One explanation is that the percentages of FoxP3 þ T reg cells in CD4T cells in the mice treated with IBM-BMT plus ATT were as high as in the mice treated with IBM-BMT alone ( Figure 5 ), although it was lowest in the mice that had received IBM-BMT plus DLI. As FoxP3 þ T reg cells have suppressive effects on GVHD, 19 the elevated proportion of FoxP3 þ T reg cells may be related to the low incidence of GVHD in the mice treated with IBM-BMT plus ATT. 23 There are two types of T reg cells: one is naturally occurring T reg (nT reg ) cells, which are derived from the thymus and the other is induced T reg (iT reg ) cells, which are induced in the periphery from FoxP3 À CD4 þ T cells. 24 It is likely that the former works predominantly in the mice treated with IBM-BMT plus ATT. However, it is still unknown how T reg cells are supplied from ATT and functionally suppress GVHD. It has been shown that nT reg cells are induced by dendritic cells, which can present autoantigens in the thymic medulla and suppress autoreactive T cells as converted negative selection. [25] [26] [27] Therefore, nT reg cells induced from ATT may be responsible for the induction of specific tolerance to host antigens. It is also conceivable that the development of nT reg cells from the transplanted thymus in allogeneic host plays a crucial role in the suppression of the antihost response. Further study is required to identify the exact mechanism involving the transfer and/or deletion of T reg cells.
Finally, we analyzed in vitro the immune functions of the mice treated with IBM-BMT plus ATT under the condition of SubLI or LDBMCI. Significant immune responsiveness to both T-cell and B-cell mitogens was observed under either condition to be comparable to those in IBM-BMT alone (Figure 6a ). In addition, the newly developed T cells showed a low response to the host but a normal response to a third party (C3H), confirming a host-specific tolerance (Figure 6b ). Although we did not perform cytokine analyses in this study, we observed earlier that IFN-g production was elevated in the mice treated with IBM-BMT plus ATT. 16 The cytokine may facilitate the engraftment of donor cells rather than promote an allo-response. The low immune response to both mitogens, but a significantly high response to the host, were observed in the mice treated with IBM-BMT plus DLI under either condition, suggesting the presence of GVHD with immunodeficiency. Thus, successful BMT could be achieved in the mice that had received IBM-BMT plus ATT under either condition.
Overall, we have shown that IBM-BMT plus ATT is superior to IBM-BMT alone under the condition of SubLI or LDBMCI. TT alone has been clinically used for the treatment of DiGeorge syndrome and HIV infection. 17, 18 From the ethical and clinical viewpoints, it would seem to be difficult to obtain the thymus and BMCs from the same young donors. However, we have recently shown that even MHC-mismatched thymus grafts can support thymopoiesis, which is comparable to a matched thymus graft. 28 In addition, there has recently been dramatic progress in research areas concerning thymus regeneration. 29, 30 Thymus grafts in conjunction with IBM-BMT may become a valuable strategy for the treatment of aged patients with various intractable diseases. 
